1643-29-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-IODOPHENYL)PROPIONIC ACID is used as a key building block for the synthesis of various drugs, primarily nonsteroidal anti-inflammatory drugs (NSAIDs). Its unique structure allows for the development of medications that can effectively manage inflammation and pain without the side effects associated with steroidal drugs.
Used in Organic Synthesis:
In the realm of organic synthesis, 3-(4-IODOPHENYL)PROPIONIC ACID is utilized as a precursor for the production of other organic compounds. Its iodine-substituted phenyl group provides a distinct chemical handle for further reactions and modifications, making it a valuable component in the creation of new molecules with specific properties.
Used in Biomolecule Modification:
3-(4-IODOPHENYL)PROPIONIC ACID is employed in the modification of biomolecules, where its chemical properties can be leveraged to alter the behavior or function of biologically relevant molecules. This can lead to the development of new therapeutic agents or diagnostic tools.
Used in Metal-Organic Frameworks and Coordination Complexes:
3-(4-IODOPHENYL)PROPIONIC ACID is studied for its potential use as a ligand in metal-organic frameworks and other coordination complexes. Its ability to coordinate with metal ions could lead to the development of new materials with unique properties, such as enhanced catalytic activity or improved stability in various applications.

InChI:InChI=1/C9H9IO2/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5H,3,6H2,(H,11,12)

Upstream product

• 34633-09-5 3-(p-iodophenyl)acrylic acid 
• 858783-43-4 3-(4-iodo-phenyl)-thiopropionic acid dimethylamide 
• 25100-55-4 2-(4-Iodobenzyl)malonic acid 
• 501-52-0 3-Phenylpropionic acid 
• 64-19-7 acetic acid 
• 7664-93-9 sulfuric acid 
• 7553-56-2 iodine 
• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 2393-17-1 3-(4-aminophenyl)propionic acid 
• 619-89-6 p-nitrocinnamic acid 

Downstream Products

• 157126-75-5 4-iodobenzenepropanoic acid,ethyl ester 
• 147949-77-7 N-(3-hydroxybenzyl)-2-<3-(4-iodophenyl)propionamido>acetamide 
• 141234-17-5 <125I>-3-(p-iodophenyl)propionic acid 
• 132513-18-9 N-[2-(3-Hydroxy-4-methoxy-phenyl)-ethyl]-3-(4-iodo-phenyl)-propionamide 
• 147949-92-6 N-<3-(4-iodophenyl)propionyl>glycine 
• 49618-02-2 3-(4-Iodo-phenyl)-propionyl chloride 
• 14548-40-4 6-iodo-2,3-dihydro-1H-inden-1-one 
• 351014-60-3 vinyl 3-(4-iodophenyl)propanoate 
• 897661-03-9 1-(3,4-dimethoxyphenylacetyl)-4-[3-(4-iodophenyl)propionyl]piperazine 
• 1252038-08-6 3-(4-iodophenyl)-1-[(2S)-2-(4-phenyl-1H-imidazol-2-yl)pyrrolidin-1-yl]propan-1-one 

Relevant academic research and scientific papers

Positive variation of the MRI signal via intramolecular inclusion complexation of a C-2 functionalized β-cyclodextrin

The synthesis of a new contrast agent based on a β-cyclodextrin scaffold and bearing a flexible lipophilic spacer arm on its secondary face is reported. Intermolecular host-guest inclusion complexes were known to undergo an enhancement of the contrast imaging. We extend this concept to intramolecular complexation. Inter- and intramolecular interactions are compared by NMR spectroscopy, circular dichroism and magnetic resonance imaging using hydrocinnamic acid and adamantane carboxylic acid as external guests. This positive variation of the observed relaxivity is a key element of new strategies aiming at developing smart molecular MRI probes.

THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF

Provided herein are compositions and methods for preparing albumin-targeting moieties that feature a thioamide linkage. Methods to use the albumin targeting molecules to generate drugs with improved in vivo pharmacodynamics and biodistribution are described. Therapeutic compounds incorporating these thioamide linked albumin-targeting moieties are disclosed.

FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS

Provided herein are compositions and methods for generating polypeptides using non-natural amino acids (nnAAs) and genetic machinery, wherein the modified polypeptides, such as therapeutic polypeptides, bind to albumin, such as serum albumin. Methods of substituting a non-natural amino acid in a first polypeptide to obtain a modified polypeptide, the nnAA in some instances comprising an albumin targeting group, are disclosed, as are methods for making populations of such modified polypeptides. A therapeutic polypeptide, interleukin-1 receptor antagonist (IL-1RA) is exemplified using the disclosed methods.

RADIOIODINATED BIOCONJUGATION REAGENTS

This disclosure relates to radioiodinated compounds useful as bioconjugation reagents, and intermediates for making radioiodinated bioconjugation reagents.

A Mild and General One-Pot Synthesis of Densely Functionalized Diaryliodonium Salts

Diaryliodonium salts are powerful and widely used arylating agents in organic chemistry. Here we report a scalable synthesis of densely functionalized diaryliodonium salts from aryl iodides under mild conditions. This two-step, one-pot process has remarkable functional group tolerance, is compatible with commonly employed acid-labile protective group strategies, avoids heavy metal and transition metal reagents, and provides a direct route to stable precursors to PET imaging agents.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

Synthesis of organometallic poly(dendrimer)s by macromonomer polymerization: effect of dendrimer size and structural rigidity on the polymerization efficiency

Two series of first to third generation (G1-G3) oligoether dendrimers, one hearing a shorter spacer chain (C-O) and the other having a longer spacer branch (C-C-C-O) were prepared. Both series of compounds, containing two reactive C≡CH moieties on the dendrimer surface, were used as macromonomers and copolymerized with trans-[Pt(PEt3)2Cl2] to form organometallic poly(dendrimer)s by an outer-sphere-outer-sphere connection strategy. It was found that concentration of monomer used in the polymerization, the dendrimer generation, and, most strikingly, the length of the spacer were key factors that determined the polymerization efficiency. Hence, the structurally more rigid and compact C-O linked dendrimers formed poly(dendrimer)s with a higher degree of polymerization than the structurally less rigid and more bulky C-C-C-O dendrimers. This result was due to the higher tendency to form cyclic oligomers in the latter series of compounds. In addition, the differences in the polymerization efficiency among the three generations of dendrimers could be explained by the gradual decrease of reactive functional group density on the dendrimer surface.

Predicting the structure of supramolecular dendrimers via the analysis of libraries of AB3 and constitutional isomeric AB2 biphenylpropyl ether self-assembling dendrons

The synthesis of 4′-hydroxy-4-biphenylpropionic, 3′,4′- dihydroxy-4-biphenylpropionic, 3′,5′-dihydroxy-4-biphenylpropionic, and 3′,4′,5′-trihydroxy-4-biphenylpropionic methyl esters via three efficient and modular strategies including one based on Ni-catalyzed borylation and sequential cross-coupling is reported. These building blocks were employed in a convergent iterative approach to the synthesis of one library of 3,4,5-trisubstituted and two libraries of constitutional isomeric 3,4- and 3,5-disubstituted biphenylpropyl ether dendrons. Structural and retrostructural analysis of supramolecular dendrimers revealed that biphenylpropyl ether dendrons self-assemble and self-organize into the same periodic lattices and quasi-periodic arrays observed in previously reported libraries, but with larger dimensions, different mechanisms of self-assembly, and improved solubility, thermal, acidic, and oxidative stability. The different mechanisms of self-assembly led to the discovery of two new supramolecular structures. The first represents a new banana-like lamellar crystal with a four layer repeat. The second is a giant vesicular sphere self-assembled from 770 dendrons that exhibits an ultrahigh molar mass of 1.73 × 106 g/mol. Thus, the enhanced size of the self-assembled structures constructed from biphenylpropyl ether dendrons permitted for the first time discrimination of various molecular mechanisms of spherical self-assembly and elaborated a continuum between small filled spheres and very large hollow spheres that is dictated by the primary structure of the dendron. The comparative analysis of libraries of biphenylpropyl ether dendrons with the previously reported libraries of benzyl-, phenylpropyl-, and biphenyl-4-methyl ether dendrons demonstrated biomimetic self-assembly wherein the primary structure of the dendron and to a lesser extent the structure of its repeat unit determines the supramolecular tertiary structure. A "nanoperiodic table" of self-assembling dendrons and supramolecular dendrimers that allows the prediction of the general features of tertiary structures from primary structures was elaborated.

Sequential Ni-catalyzed borylation and cross-coupling of aryl halides via in situ prepared neopentylglycolborane

(Chemical Equation Presented) A procedure for NiCl2(dppp)- catalyzed pinacolborylation and neopentylglycolborylation that utilizes in situ prepared inexpensive pinacolborane and neopentylglycolborane is reported. The scope of this reaction was demonstrated with a variety of aryl bromides and iodides. The resulting aryl neopentylglycolboronic esters undergo a NiCl 2(dppe)-catalyzed cross-coupling with aryl halides, resulting in an extremely efficient and cost-effective method for the synthesis of functional biaryls, dendritic building blocks, and other complex architectures.

Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes

A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA1) has been discovered and explored. The preferred compound 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.